NextBiotix is a French biotechnology company specializing in the development of a new class of medications derived from bacteria in the human gut microbiome, aimed at treating chronic inflammatory bowel diseases.
The Nomen agency was consulted to assist the four founders in renaming the company
Exeliom evokes the pursuit of scientific excellence that drives the company daily. The name subtly suggests the theme of the “microbiome” through the central letters “i” and “o.” The ending “-om” further emphasizes the commitment to working with and for humanity.
